Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

Assuntina G. Sacco, Ruifeng Chen, Francis P. Worden, Deborah J.L. Wong, Douglas Adkins, Paul Swiecicki, Wanxing Chai-Ho, Peter Oppelt, Debanjali Ghosh, Julie Bykowski, Alfredo Molinolo, Emily Pittman, M. Valeria Estrada, Kathryn Gold, Gregory Daniels, Scott M. Lippman, Amanda Natsuhara, Karen Messer, Ezra E.W. Cohen

Research output: Contribution to journal › Article › peer-review

80 Scopus citations

Fingerprint

Dive into the research topics of 'Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences